2014. október 20., hétfő 10:00 |
Manage Your Reflux Symptoms: The Food4GERD app |
|
Zurich, 20 October, 2014 (APA/OTS) - Gastroesophageal reflux
disease (GERD), often referred to as heartburn, is a major issue for
many people worldwide.(1) Choice of foods(2) and eating habits(3)
may have an impact on GERD symptoms. Takeda has developed the mobile
application Food4GERD to assist people to manage their reflux
symptoms. |
- Cross reference: Picture is available at epa european
pressphoto agency (http://www.epa.eu) and
http://www.presseportal.de/pm/111920/ -
The Food4Gerd app is a mobile application that provides insights
into common foods and beverages, making it a helpful tool for
checking ingredients and their possible effects on reflux symptoms.
It is commonly known that gradual dietary and lifestyle changes are
recommended to improve GERD-related symptoms(4).
The "Ingredient Check" included in the Food4GERD app helps sufferers
to observe which of their preferred food choices are good ones and
which should be avoided. In the latest version, patients can also
add their own foods and beverages and protect access to the app with
a pin-code.
An integrated "Symptom Tracker" allows users to record the severity
of reflux symptoms such as heartburn, sore throat or chest pain. In
addition, the app offers the possibility to track times of symptom
occurrence, as well to define personal triggers e.g. stress or
irregular eating, and ingredients that may be related to the
symptoms. A personal diary can be reviewed in the "Symptom History"
and all data can be exported, which is a helpful tool as patients
can use the results for discussion with their physicians: Using the
Food4GERD app as part of the follow up communication between
patients and physicians about the course of disease will support
both to optimize treatment(5).
The Food4GERD app is available for all common mobile devices
(including IOS and Android). It recently received its first Spanish
language update, with more translations to follow. For more
information please visit www.food4gerd.com.
About GERD
Gastroesophageal reflux disease (GERD) or acid reflux disease (ARD),
is a common condition that develops when reflux of stomach contents
causes troublesome symptoms or complications.(6) Common symptoms
are e.g. pain or burning in the chest and difficulties in
swallowing, yet untreated GERD may result in asthma, voice change or
hoarseness.(7)
The prevalence of GERD has increased over the last 20 years(8),
mainly in western industrialized nations 1,8, and affects all ages.7
Prevalence estimates range from 18-28% in North America and 9-26% in
Europe.1
About Takeda Pharmaceuticals International GmbH
Headquartered in Zurich as a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, Osaka, Japan; the company has a
commercial presence covering more than 70 countries, with particular
strength in Asia, North America, Europe and fast-growing emerging
markets including Latin America, Russia-CIS and China. Areas of
focus include cardiovascular and metabolic, oncology, respiratory
and immunology, central nervous system, general medicine, and
vaccines.
Takeda is a research-based global company with its main focus on
pharmaceuticals. As the largest pharmaceutical company in Japan and
one of the global leaders of the industry, Takeda is committed to
strive towards better health for people worldwide through leading
innovation in medicine. Through the integration of Millennium
Pharmaceuticals and Nycomed, Takeda has been transforming itself,
broadening its therapeutic expertise and geographic outreach. Additional information about Takeda is available through its
corporate website, www.takeda.com.
Contacts: m:werk GmbH & Co. KG Humboldtstraße 11 D-65189 Wiesbaden Tel.: +49 (0)611-16086-0 Fax: +49 (0)611-16086-15 Email: reflux@m-werk.de
(1) El-Serag HB et al. Gut, 13 Jul 2013 (Epub ahead of print);
doi:10.1136/gutjnl-2012-304269. (2) Mansour-Ghanaei F et al. Int J Mol Epidemiol Genet 2013;
4:175-182. (3) Fujiwara Y et al. Am J Gastroenterol 2005; 100:2633-2636. (4) Heidelbaugh JJ et al. Am Fam Physician 2003; 68:1311-1318. (5) McColl E et al. Am J Gastroenterol. 2005; 100:11-18. (6) Vakil N et al. Am J Gastroenterol 2006; 101:1900-1920. (7) Koop H et al. Z Gastroenterol 2005; 43:163-164. (8) El-Serag HB. Clin Gastroenterol Hepatol 2007; 5:17-26.
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
Forrás: OTS Üzleti Sajtószolgálat
MTI © Minden jog fenntartva.
|